CHICAGO, July 15, 2011 /PRNewswire/ -- Zacks Equity Research highlights Ardea Biosciences Inc (Nasdaq: RDEA) as the Bull of the Day and CenturyLink (NYSE: CTL) as the Bear of the Day. In addition, Zacks Equity Research provides analysis Edwards Lifesciences Corporation (NYSE: EW), Medtronic (NYSE: MDT) and Boston Scientific (NYSE: BSX).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
We are upgrading Ardea Biosciences Inc (Nasdaq: RDEA) to Outperform from Neutral due to the promise shown by its lead pipeline candidate lesinurad, which is being developed for treating hyperuricemia and gout. Lesinurad, which has performed well in clinical studies, will target a market with huge unmet need on approval.
The current therapies have limited efficacy with many gout patients failing to respond favorably to these therapies. This should provide lesinurad with the opportunity to take away share from currently approved therapies.
The impressive balance sheet at Ardea, which has been strengthened by the signing of the lucrative agreement with Bayer, is another positive for the company. We believe that the current price represents an attractive entry point for long-term investors.
We are downgrading our recommendation on CenturyLink (NYSE: CTL) to Underperform. First quarter earnings surpassed the Zacks Consensus Estimate aided by synergies from Embarq but fell year over year.
Although CenturyLink continues to grow its broadband customer base and associated revenues, it remains challenged by the decline in fixed voice access lines. CenturyLink's core local phone business has slowed significantly, which is evident from the consistent decline in access lines on an organic basis. Moreover, the company faces intense competition from cable TV operators.
We also remain cautious regarding the carrier's high debt exposure, which adds a degree of financial risk. Our price target of $36 is based on 13.3x our earnings estimate for 2011.
Latest Posts on the Zacks Analyst Blog:
Edwards Lifesciences Corporation (NYSE: EW) received 510 (k) clearance from the US Food and Drug Administration (FDA) for its EV1000 clinical monitoring platform.
The device is meant to help physicians make prompt and judicious decisions in the operating room.
Edwards is one of the leading players in hemodynamic monitoring equipment, used to measure a patient's heart function in surgical and intensive care settings. The need to monitor arises before, during and after open-heart, major vascular, major abdominal, neurological and orthopedic surgical procedures. The company also offers the Flotrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology.
In late 2010, Edwards introduced its VolumeView sensor-catheter set and EV1000 clinical monitoring platform in Europe and Australia, which expanded the medical intensive care portfolio. During the first quarter of fiscal 2011, sales of Critical Care increased 14.8% year over year, which came in at $120.6 million. Strong sales of advanced monitoring products led by Flotrac systems and pressure monitoring products contributed to the growth.
The company expects Critical Care to record revenues at the higher end of a $470−$500 million range, resulting in 5%−8% underlying sales growth in 2011, driven by ongoing growth of advanced monitoring products and the recent launch of VolumeView and EV1000. With these products fetching positive clinician feedback, they could drive market share going ahead. Approval of EV 1000 in US should result in higher revenues from the segment in the forthcoming period. Moreover, Edwards is making progress with respect to second generation product of its glucose monitoring program and expects to receive CE Mark approval by the end of 2011.
While it is encouraging to note that the Critical Care segment is on a growth path, Edwards records the majority of its revenues from the Heart Valve Therapy segment. In this respect, the company is awaiting an FDA panel's recommendation for its Sapien transcatheter heart valve (THV), scheduled on July 20, 2011. However, the company operates in a highly competitive environment with many big players such as Medtronic (NYSE: MDT) and Boston Scientific (NYSE: BSX) targeting the THV business.
We are currently 'Neutral' on Edwards, which also corresponds to Zacks #3 Rank (hold) in the short term.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
Share this article